ADC Therapeutics SA

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with their next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, they are working to address significant unmet medical needs and improve outcomes for…More those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Their highly skilled global team is committed to confronting cancer with the full potential of their science, bringing unique, targeted therapies and hope to patients and their families.